Hi Gary,
It’s a drug, and not a procedure. If it were just a procedure NWBO could just sell machinery and let clinics figure out the best ways to use dendritic cells however they want. A drug, approved to be manufactured to strict specifications. A manufacturer of a licensed drug makes a drug, they do not sell machines to random hospitals to make it for them. In a trial that is fine with the university developing the treatment, UCLA. They likely gave them a limited purpose license, but that won’t extend into a licensed drug.
As for what NWBO will build, they don’t have to disclose it to us, but they have to have a plan for commercialization. They have been very clear about their expectations for Sawston in their disclosures. They also have a co-development financing arrangement already in place with the local development authority, and that allows for a development plan that is opportunistic and utilized local demand for some of the initial development revenues to sustain the place until they have enough volume and then probably still they would provide those services in the small footprint that has already been developed.
I won’t comment on NWBO’s direct cost of each machine after development costs, but it could be not all that great after all of the time developing both the technology and all the relevant contracts and maintaining that systems and IP. Probably making the actual machines themselves are the least of all of those cumulative expenses.
News 
Market Data 
Discover 
